Irisin suppresses the expression of proinflammatory genes and decreases the release of proinflammatory cytokines in patients with abdominal obesity and T2DM, thereby attenuating adipose tissue and vascular inflammation and improving insulin resistance, liver function and endothelial function [17,18]. The gene discussed is FNDC5; the disease is Insulin resistance.